-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Industry News & Regulatory Approvals
-
Regulatory News for Nov. 23, 2022
US Food and Drug Administration approves two combinations for non-small cell lung cancer.
-
Real-World Data from Taiwan Shows Stage Shift Has Improved Lung Cancer Survival Rates
Researchers say increased screening of at-risk populations, including those who have never smoked, may improve survival more than any other strategy.
-
US FDA’s Review of Single-Country ‘Me Too’ Drugs: A Clinical Trialist Perspective
With no direct comparison to the standard of care and limited resources to review applications, researchers say they support the agency’s decision not to approve sintilimab.
-
In Brief for May 25, 2022
5th edition of patient education book released; US FDA moves to prohibit tobacco flavoring.
-
In Brief for May 11, 2022
Winship Cancer Institute announces preceptor opportunity. NICE recommends tepotinib for select patients.
-
The FDA Explained: An Interview with Dr. Harpreet Singh
During an episode of IASLC’s Lung Cancer Considered podcast, Dr. Singh provided insight into the US agency’s approval process. Here are some highlights.
-
US FDA greenlights nivolumab for use before surgery for NSCLC
Approval opens the door for an immunotherapy-based treatment option prior to surgery for the first time.
-
Regulatory News for February 23, 2022
Taiwan OKs nivolumab IV infusion in some cases. UK approves atezolizumab for NSCLC. European Commission greenlights lorlatinib for advanced ALK-positive disease.
-
Regulatory News for February 9, 2022
Sotorasib earns approval in European Union, Japan. Scotland OKs osimertinib.
-
New Warranty, Rebate Programs Put Spotlight on Value in Lung Cancer
Value-based care is getting more attention in lung cancer thanks to two new programs offering significant rebates or full refunds should the therapeutic agent be ineffective or intolerable. Pfizer’s pilot project, a U.S.-based program that runs through the end of the year, covers the cost of Xalkori (crizotinib) paid by the patient, Medicare, or private…